Assessing the SCLC Treatment Landscape Best of AACR Annual Meeting Biochemical Recurrence in Prostate Cancer Combination Strategies in Metastatic RCC R/R HER2+ Metastatic Breast Cancer Case Review

Assessing the SCLC Treatment LandscapeBest of AACR Annual MeetingBiochemical Recurrence in Prostate Cancer Combination Strategies in Metastatic RCCR/R HER2+ Metastatic Breast Cancer Case Review

Clinical

View More Brain Cancer Breast Cancer Colorectal Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Hematology Leukemia Lung Cancer Lymphoma Pediatric Cancers Skin Cancer

Brain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer

News

All News NP/PA Practice Management Technology

All NewsNP/PAPractice ManagementTechnology

Media

Around the Practice Clinical Consult Enduring Webinars Expert Interviews Medical World News OncView Podcasts Readout 360 Tumor Board Series

Around the PracticeClinical ConsultEnduring WebinarsExpert InterviewsMedical World NewsOncViewPodcastsReadout 360Tumor Board Series

Conferences

Publications

About Oncology Journal MBCC Abstract Supplement Oncology Journal

About Oncology JournalMBCC Abstract SupplementOncology Journal

Events

Live Events Virtual Events

Live EventsVirtual Events

CME/CE

Resources

Image IQ Polls Quizzes Slideshows Sponsored Toolkits

Image IQPollsQuizzesSlideshowsSponsoredToolkits

eNewsletter Print Subscription

eNewsletterPrint Subscription

CureToday.com
OncLive.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Spotlight

Assessing the SCLC Treatment Landscape
Best of AACR Annual Meeting
Biochemical Recurrence in Prostate Cancer
Combination Strategies in Metastatic RCC
R/R HER2+ Metastatic Breast Cancer Case Review

ClinicalSee All >

Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer

CureToday.com
OncLive.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Amy K. Erbe, PhD | Authors

BAY REGIONAL MEDICAL CTR

1900 COLUMBUS AVE

Articles

Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma

April 08, 2017

This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.